Cambridge, UK and Deqing, China, April 26, 2018 : Abcam, an innovator in reagents and tools, today signed a Memorandum of Understanding (MoU) with Shuwen Biotech, a leading player in the development and commercialization of companion diagnostics (CDx). Through the agreement, Abcam and Shuwen will jointly leverage their respective capabilities, in producing high-quality antibodies and CDx kit development and commercialization, to better serve the needs of the pharma industry.
The two parties are responding to the increasing range of development needs from pharmaceutical and biopharma developers, patients, healthcare professionals, and regulatory authorities, The nature of any joint work is yet to be determined in detail but is likely to encompass Abcam providing reproducible highly-specific recombinant antibodies to key targets, which Shuwen will incorporate into companion diagnostic kits.
"Shuwen has a long-standing reputation amongst pharmaceutical companies for companion diagnostic kit development and central lab testing, and Abcam is a recognized leader in quality antibody development. This alliance will undoubtedly further strengthen Shuwen’s capabilities in developing quality companion diagnostic kits especially immunoassay kits,” said Jay Z. Zhang, Shuwen’s Chief Executive Officer and Chairman. “We have seen continuous advances at all levels in personalized medicine over the past few years and these can only continue through innovative technologies like those that will be born out of joint efforts between Shuwen and Abcam.”
John Baker, Abcam's SVP Portfolio and Business Development said:“Abcam is pleased to establish this long-term collaborative strategic partnership, combining our unique capabilities to develop sensitive, highly-specific and validated antibodies with Shuwen’s proven track-record in the CDx space. Our work with Shuwen will focus on developing efficient and comprehensive solutions to advance clinical diagnostics and precision medicine, faster."
About Shuwen Biotech
Shuwen Biotech is a China-based diagnostics company founded on the principles of innovation, patent protection, and international collaboration as its strategic platforms for growth. Since 2011, Shuwen established strategic partnerships with numerous outstanding academic and commercial institutions such as Yale University, University of Chicago, Max-Plank Institute, BioNTech among others in the form of exclusive licensing of over 20 first-in-class diagnostic technologies and 50+ patents covering a range of novel biomarkers for companion diagnostics and other diagnostics in the fields of cancer, women’s health, critical care, and health screening and other fields. Shuwen houses an in-house development team, CAP-accredited central lab, and IVD manufacturing facilities all in line with global standards in order to continue to deliver transformational products to its customers globally and open new possibilities in the advancement of health.
To learn more, visit http://shuwenbiotech.com/